Teladoc price target raised to $62 from $51 at Citi. Citi analyst Stephanie Demko raised her price target for Teladoc to $62 and reiterates a Buy rating on the shares following the company’s acquisition of Advance Medical. The analyst views the purchase price as reasonable. The acquisition makes Teladoc the sole global telehealth player while also expanding the company’s telehealth solution suite into home care, wellness, and chronic care, Demko investors in a research note.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.